Trial Profile
A Phase I Open-Label Multicentre Study to Assess the Pharmacokinetics and Safety of Naloxegol in Paediatric Patients Ages ≥ 6 Months to < 18 Years Receiving Treatment With Opioids
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Naloxegol (Primary)
- Indications Constipation
- Focus Pharmacokinetics
- Acronyms KODIAK16
- Sponsors AstraZeneca; Kyowa Kirin International; Kyowa Kirin Pharmaceutical Development
- 16 Oct 2022 This trial has been discontinued in Spain (End Date: 13 Dec 2021) according to European Clinical Trials Database record.
- 26 May 2022 Status changed from active, no longer recruiting to completed.
- 15 Nov 2021 Planned End Date changed from 1 Nov 2021 to 1 Apr 2022.